CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Apremilastdrug
Likely dose
Apremilast 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03239106
NCT03239106Phase 2Completed
CompareCT.gov

An Open Label Study of Apremilast in Chronic Idiopathic Pruritus

Washington University School of Medicine·interventional·Posted Aug 3, 2017·Updated Jul 13, 2021

In Brief

A Phase 2 clinical trial evaluating Apremilast for Itch. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Chronic Itch is a debilitating condition affecting many people. Currently, there are no FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic arthritis. This study examines if apremiliast taken twice daily relieves chronic itch.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsItch
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 3, 2017
Enrollment StartDec 1, 2017
Primary CompletionOct 31, 2018
Study CompletionSep 19, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.9 years ago

Interventions

Apremilastdrug

Apremilast 30 mg BID daily